CancerCast

Weill Cornell Medicine

New scientific developments are transforming the future of cancer treatment and care. Hosted by world-renowned medical oncologist Dr. Manish Shah, CancerCast is your window into research breakthroughs, innovative therapies, and honest accounts of living with and beyond cancer.

  1. 1d ago

    Cancer Survivorship – Living With and Beyond Cancer

    Thanks to advances in cancer care, more people are living longer after a cancer diagnosis than ever before. People are also being diagnosed at earlier ages, leading to an increased number of cancer survivors worldwide. In this episode of CancerCast, Dr. Manish Shah speaks with Dr. Emily Tonorezos about the growing field of cancer survivorship and what it means to live well after a cancer diagnosis. Cancer is a chronic condition that requires unique management and continued care. They discuss some of the late effects of cancer treatment that can sometimes persist well after active treatment is completed, like fatigue, neuropathy, fertility, accelerated aging, heart health, emotional well-being, and overall quality of life. The conversation also explores how exercise, nutrition, and other lifestyle habits may help cancer survivors improve general wellness and reduce the long-term health risks of cancer treatment, including risk of secondary cancers or cancer recurrence. Learn more about the goals of cancer survivorship care plans, what researchers are discovering about life after cancer, and why survivorship is becoming one of the fastest-growing areas in cancer care. Guest: Emily Tonorezos, MD, MPH, Director of the Iris Cantor Cancer Survivorship Program at Weill Cornell Medicine. Host: Manish Shah, MD, Chief of Solid Tumor Service and Director of Gastrointestinal Oncology at Weill Cornell Medicine and NewYork-Presbyterian Hospital.

  2. May 22

    Understanding Clonal Hematopoiesis: Blood Mutations Linked to Cancer, Heart Disease, Inflammation & More

    As we age, our blood cells naturally develop mutations. With new sequencing technology, we can now identify very rare and specific mutations in human blood more easily and precisely than ever before. It’s like we now have a path to find the needle in a haystack. Researchers have discovered that some of these age-related blood mutations, collectively known as clonal hematopoiesis, may be linked to increased risk of blood cancer, heart disease, stroke, and chronic inflammation. In this episode of CancerCast, Drs. Manish Shah and Pinkal Desai explain what clonal hematopoiesis is and why clonal hematopoiesis of indeterminant potential or “CHIP” is being detected more often through advanced blood testing and multi-cancer early detection (MCED) blood tests. They break down what patients should understand if these mutations appear in liquid biopsy results or screening tests and explain why certain patients should consider being monitored for these mutations. Research into clonal hematopoiesis and CHIP is raising important questions about cancer risk, prevention, and long-term monitoring for cardiovascular and inflammatory diseases. The conversation explores potential health consequences of these blood mutations, the connection between the heart and blood, as well as why CHIP can worsen existing health conditions from autoimmune disorders to gout and beyond. Focused CHIP research efforts are underway to try to better detect and prevent blood cancers such as leukemia and myelodysplastic syndromes (MDS), as well as to intervene earlier for healthy and optimal aging. Guest: Pinkal Desai, MD, Clinical Director, Englander Institute for Precision Medicine Molecular Aging Institute and hematologist/oncologist caring for patients with leukemia and other blood cancers at Weill Cornell Medicine and NewYork-Presbyterian Hospital. Host: Manish Shah, MD, Chief of Solid Tumor Service and Director of Gastrointestinal Oncology at Weill Cornell Medicine and NewYork-Presbyterian Hospital.

  3. Apr 27

    What are the Latest Advances in Lung Cancer Treatment?

    Lung cancer care is changing rapidly and new advances in surgery and medicine are at the forefront. In this episode of CancerCast, Dr. Manish Shah is joined by two lung cancer experts, Drs. Jonathan Villena and Christine Garcia, to explore how innovations in surgery, biomarker testing, targeted therapy, and immunotherapy are transforming outcomes for patients with lung cancer. The conversation covers the importance of early detection through screening, as well as new tests, tools and technologies to ensure lung cancer patients are getting the right treatment at the right time. From cutting-edge single port robotic surgeries that avoid the ribs and preserve healthy lung tissue to personalized, targeted therapies rooted in the molecular footprint of each tumor, options and outcomes for patients with lung cancer continue to drastically improve. The team discusses everything from reducing recovery time after an operation, to optimizing results with novel therapies, and the importance of a multidisciplinary care team to ensure patients have the best possible treatment and outcomes. Guests: Christine Garcia, MD, MPH, medical oncologist caring for lung cancer patients at Weill Cornell Medicine and NewYork-Presbyterian Hospital. Jonathan Villena-Vargas, MD, cardiothoracic surgeon at Weill Cornell Medicine and NewYork-Presbyterian Hospital. Host: Manish Shah, MD, Chief of Solid Tumor Service and Director of Gastrointestinal Oncology at Weill Cornell Medicine and NewYork-Presbyterian Hospital.

  4. Mar 20

    Understanding BiTE Immunotherapy: How Bispecific T-Cell Engagers Target Cancer

    Bispecific T-cell engager, or BiTE, therapy is an immunotherapy approach that helps the body’s own immune system target cancer cells by bringing immune cells and cancer cells together. In this episode of CancerCast, Dr. Manish Shah is joined by Dr. Mateo Mejia to explain how this form of antibody-based treatment works by directly connecting T cells and cancer cells. It is a new treatment in the arsenal of immunotherapy to treat cancer. They explore common side effects, as well as similarities and differences between BiTEs and other forms of immunotherapy. BiTE immunotherapy prevents cancer cells from being able to hide from the natural immune system, helping it to better recognize and attack the cancer. BiTEs are becoming an important treatment tool for several cancers, including multiple myeloma, lymphoma, lung cancer, and uveal melanoma. Drs. Shah and Mejia discuss the future direction and expansion of BiTE therapy, including ongoing research to bring these treatments to patients earlier in their cancer treatment journeys. Guest: Mateo Mejia Saldarriaga, MD, Assistant Professor of Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine and an Assistant Attending Physician at NewYork-Presbyterian Hospital. Host: Manish Shah, MD, Chief of Solid Tumor Service and Director of Gastrointestinal Oncology at Weill Cornell Medicine and NewYork-Presbyterian Hospital.

  5. Feb 13

    The Power of PSMA-Targeted Therapy for Prostate Cancer

    Prostate-specific membrane antigen, or PSMA, is a protein expressed on the surface of prostate cancer cells that has become an important target for both diagnosing and treating the disease. In this episode of CancerCast, Dr. Manish Shah speaks with prostate cancer expert Dr. Scott Tagawa about how this PSMA protein helps identify whether prostate cancer is confined to the prostate or has spread, and the ways it can be used to guide treatment decisions. They discuss how PSMA-based prostate cancer treatments work in the body and why these therapies have become one of the most significant recent advances in modern medicine for prostate cancer. Guest: Scott Tagawa, MD, MS, Director of the Genitourinary Oncology Program and Medical Director of the Genitourinary Oncology Research Program at Weill Cornell Medicine/NewYork-Presbyterian Hospital. Host: Manish Shah, MD, Chief of Solid Tumor Service and Director of Gastrointestinal Oncology at Weill Cornell Medicine and NewYork-Presbyterian Hospital.

  6. Jan 14

    The Treatment Toolkit for Liver Cancer and Metastatic Disease, from Surgery to Shockwaves and Beyond

    Discover how liver cancer treatment is evolving in this episode of CancerCast. Dr. Manish Shah and Dr. Juan Rocca discuss the liver’s complicated and critical role in cancer care, from its position as a hotspot for metastasis to the role of the liver in impacting how well certain immunotherapy, chemotherapy and other cancer therapies will work. They explore the newest and most cutting-edge treatment options as part of a growing toolkit to personalize treatment for each patient, including open and robotic liver surgery, ablation, and no-cut technologies like histotripsy, using ultrasound shockwaves to liquefy liver tumors while sparing healthy tissue. The conversation also highlights the role and rise of liver transplantation for select cancers, such as colorectal cancer that has spread (metastasized) to the liver, in addition to tumors that start in the liver. There have been many recent treatment advances for both primary liver cancer and metastatic disease, and Drs. Rocca and Shah discuss how combining these new innovations with a team-based, multidisciplinary approach offers patients more options than ever before. Guest: Juan Rocca, MD, Surgical Director of the Weill Cornell Liver Cancer Program and an attending surgeon in the Division of Liver Transplantation and Hepatobiliary Surgery at NewYork-Presbyterian/Weill Cornell Medicine. Host: Manish Shah, MD, Chief of Solid Tumor Service and Director of Gastrointestinal Oncology at Weill Cornell Medicine and NewYork-Presbyterian Hospital.

  7. 12/03/2025

    Key Insights from ASH 2025

    In this episode of CancerCast, Dr. Manish Shah is joined by Drs. Gail Roboz and Rick Furman, two internationally renowned Weill Cornell leaders in advancing therapies for leukemia and lymphoma, to preview groundbreaking research from the 2025 American Society of Hematology (ASH) Annual Meeting. Drs. Roboz and Furman highlight some of the most impactful abstracts to be presented during the meeting, detailing how these key research developments are poised to impact patients and the hematology field at-large. Tune in to hear more about the cutting-edge science with expert insights into how these innovations are transforming cancer care. The ASH annual meeting is the largest medical conference in the world dedicated to malignant and benign hematology, bringing together over 30,000 experts from around the world to share the latest research and advancements. Abstracts and studies discussed in this episode include PARADIGM, AML17, AML19, KOMET-007, CaDAnCe-101, CLL17, R-pola-glo, FLAIR, and more. Gail Roboz, MD, Director of the Clinical and Translational Leukemia Program at Weill Cornell Medicine/NewYork-Presbyterian Hospital. Richard Furman, MD, Director of the Chronic Lymphocytic Leukemia (CLL) Research Center at Weill Cornell Medicine. Host: Manish Shah, MD, Chief of Solid Tumor Service and Director of Gastrointestinal Oncology at Weill Cornell Medicine and NewYork-Presbyterian Hospital.

  8. 11/21/2025

    Liquid Biopsy: Cancer’s Clues in the Blood

    A liquid biopsy is a blood test that looks for cancer cells or genetic material, such as DNA, that are shed into the bloodstream in patients with cancer. In this episode of CancerCast, Dr. Massimo Cristofanilli and Dr. Manish Shah explore how liquid biopsies unlock real-time insights into cancer evolution through molecular diagnostics, painting a more comprehensive and holistic picture of what’s going on with cancer inside the body, and often much earlier than other imaging tools. By analyzing circulating tumor cells, cell-free DNA or circulating tumor DNA, liquid biopsies can offer many clues that may predict cancer recurrence, guide treatment decisions, or detect resistance to certain treatments. Learn more about how this evolving non-invasive technology enables more personalized care for patients. Guest: Massimo Cristofanilli, MD, Associate Director of Precision Oncology at the Weill Cornell Medicine Meyer Cancer Center (MCC), Co-Leader of the MCC Breast Cancer Disease Management Team and Scientific Director of the Englander Institute for Precision Medicine (EIPM) Host: Manish Shah, MD, Chief of Solid Tumor Service and Director of Gastrointestinal Oncology at Weill Cornell Medicine and NewYork-Presbyterian Hospital. Learn more about Massimo Cristofanilli, MD.

See All (76)

4.9
out of 5
30 Ratings

About

New scientific developments are transforming the future of cancer treatment and care. Hosted by world-renowned medical oncologist Dr. Manish Shah, CancerCast is your window into research breakthroughs, innovative therapies, and honest accounts of living with and beyond cancer.

Information

  • Creator
    Weill Cornell Medicine
  • Years Active
    2018 - 2026
  • Episodes
    76
  • Rating
    Clean
  • Copyright
    © Weill Cornell Medicine
  • Show Website
    CancerCast

More From Weill Cornell Medicine

You Might Also Like